Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novartis
Pharma
2025's top biopharma M&A deals
Looming patent expirations and a thawing of the biotech investment scene prompted drug developers of all stripes to pull out their checkbooks in 2025.
Fraiser Kansteiner
,
Zoey Becker
,
Angus Liu
,
Kevin Dunleavy
,
Eric Sagonowsky
,
Andrea Park
Jan 12, 2026 3:00am
Novartis charts next US investment with new radiopharma plant
Jan 9, 2026 10:30am
2024's top biopharma M&A deals
Brought to you by
Pfizer
Novartis to cut 550 jobs at Swiss facility by end of 2027
Nov 25, 2025 10:18am
Novartis scores FDA approval for new version of SMA gene therapy
Nov 25, 2025 10:02am
Novartis to set up manufacturing hub in NC, add 700 jobs
Nov 19, 2025 2:30pm